Ana Oaknin
0000-0002-3592-7194
Publication & Citation Trends
Publications
0 total
Abstract P1-01-18: Prevalence of functional HRD by the RAD51 assay: a pooled analysis with 367 patients from BRCA-associated tumor types
Cited by 0
Semantic Scholar
561P Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Cited by 0
Semantic Scholar
147 Evolution of phase 1 clinical trials for head and neck cancer patients based on the experience of a dedicated phase I Unit.
Cited by 0
Semantic Scholar
790P The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
Cited by 0
Semantic Scholar
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. OA
Cited by 14
Semantic Scholar
2314P Quality and safety of research biopsies (RB) in oncology clinical trials OA
Cited by 0
Semantic Scholar
Representation of young adult(19–29 y) and elderly(>75 y) patients populations in an early drug development unit OA
Cited by 0
Semantic Scholar
Identification of homologous recombination deficiency (HRD) by RAD51 in a tumor molecular profiling program for precision medicine.
Cited by 1
Semantic Scholar
Research Topics
Ovarian cancer diagnosis and treatment
(353)
PARP inhibition in cancer therapy
(265)
Endometrial and Cervical Cancer Treatments
(171)
Cancer Genomics and Diagnostics
(137)
Cancer Immunotherapy and Biomarkers
(86)
Affiliations
Université Claude Bernard Lyon 1
AstraZeneca (United Kingdom)
Creighton University
Universitat de Vic - Universitat Central de Catalunya
Roche (Switzerland)